-
Diagnostics World | As the body’s stress hormone, cortisol influences several diseases, from chronic illnesses, such as diabetes and cancer; to mental illnesses, such as depression; to neurological diseases, such as Alzheimer’s disease. Researchers at Aarhus University have discovered a breakthrough method to measure cortisol in an efficient, faster way.
Apr 11, 2024
-
Diagnostics World | During the NVIDIA GTC conference held at the San Jose Convention Center and online March 18-21, NVIDIA CEO Jensen Huang highlighted an array of advancements, including new foundation models coming to NVIDIA BioNeMo, a collaboration with Johnson & Johnson MedTech to expand AI’s role in surgical settings, and the launch of over two dozen generative AI microservices to advance areas like digital health, medical technology, and drug discovery.
Apr 9, 2024
-
Diagnostics World | A wearable device measuring movement at the wrist can detect clear differences in people who do and don’t have beta-amyloid deposition in their brain. The discovery was enabled by a relatively new statistical technique revealing time-of-day changes in activity levels not captured by standard methods focused on average levels of activity across the day.
Apr 4, 2024
-
Diagnostics World | Study sponsors making choices about if, when, and how to include brain monitoring in their clinical studies do not often ground those choices in science or optimize for subject safety and trial de-risking. The key problem is a lack of electroencephalogram (EEG) expertise with no guidance from the Food and Drug Administration (FDA) to mitigate the situation.
Apr 3, 2024
-
Diagnostics World | You might be forgiven for calling the tone of a panel on diagnostics held at last week’s Precision Medicine Tri-Con “optimistic”. But you would be corrected: it isn’t optimism, it’s math.
Apr 2, 2024
-
Diagnostics World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; X-Therma plan to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations; and more.
Mar 27, 2024
-
Diagnostics World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; X-Therma plan to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations; and more.
Mar 26, 2024